Good pick up on the 10k. I agree with your assumption. Libigel success and the revenue the CV and HSDD benefits could generate would allow Biosante to acquire or create a Marketing Division for the company. This would be a big step towards playing with the big boys allowing to keep more of the profits. Remember Biosante still has the Global rights to Elestrin an Bio-t-gel outside the U.S.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.